<DOC>
	<DOCNO>NCT01105286</DOCNO>
	<brief_summary>The purpose trial compare anti-psoriatic effect eight different formulation vitamin D analogue use psoriasis plaque test design</brief_summary>
	<brief_title>A Psoriasis Plaque Test Comparing Eight Different Formulations Vitamin D Analogues Treatment Psoriasis</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<mesh_term>Calcipotriene</mesh_term>
	<criteria>Subjects understand sign informed consent form . Either sex Age 18 year All skin type ethnic origin Subjects diagnosis psoriasis vulgaris lesion locate arm , legs trunk . Females pregnant , wish become pregnant study , breast feeding Systemic treatment biological therapy ( market market ) possible effect psoriasis vulgaris within 4 week ( etanercept ) , 2 month ( adalimumab , alefacept , infliximab ) , 4 month ( ustekinumab ) 4 weeks/5 halflives ( whichever longer ) experimental biological product prior randomisation Systemic treatment therapy biologicals , potential effect psoriasis vulgaris ( e.g. , corticosteroid , vitamin D analogue , retinoids , immunosuppressant ) within 4week period prior randomisation Subjects use one follow topical drug treatment psoriasis within 4 week period prior randomisation study : Potent potent ( WHO group IIIIV ) corticosteroid PUVA Grenz ray therapy Subjects use one follow topical drug treatment psoriasis within two week prior randomisation study : WHO group III corticosteroid ( except use treatment scalp psoriasis ) Topical retinoids Vitamin D analogues Topical immunomodulators ( e.g . macrolides ) Anthracen derivative Tar Salicylic acid UVB therapy Subjects know nonresponder topical vitamin D analogue ( e.g. , known history improvement worsen psoriasis e.g. , calcipotriol , calcitriol tacalcitol use accord current SmPc ) Subjects receive treatment nonmarketed drug substance ( i.e. , agent yet make available clinical use follow registration ) within 4 week period prior randomisation longer , class substance require long washout define ( e.g. , biological treatment ) Subjects current participation interventional clinical , base interview subject Subjects current diagnosis guttate , erythrodermic , exfoliative pustular psoriasis Subjects know suspected hypersensitivity component ( ) investigational product Subjects known/suspected disorder calcium metabolism associate hypercalcaemia Subjects know severe hepatic and/or severe renal insufficiency Subjects concomitant medical dermatological disorder ( ) might preclude accurate evaluation psoriasis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
</DOC>